Additional CEO Share Purchase

Renalytix CEO bought 500 ADS, now holds 0.58% of the company’s shares.

What the company is saying

Renalytix plc discloses that CEO James McCullough purchased 500 American Depositary Shares (ADS) on 11 and 15 September 2026, at an average price of US$4.30 per ADS. The company details the transaction breakdown: 250 ADS at $4.42 on 11 September and 250 ADS at $4.17 on 15 September, totaling $2,148. Following these purchases, McCullough’s interest stands at 3,472,096 Ordinary Shares, representing 0.58% of issued share capital, including shares held via The McCullough 2020 Irrevocable Trust. The announcement emphasizes the CEO’s ongoing personal investment in the company. Renalytix also highlights its kidneyintelX.dkd product, which has FDA approval and Medicare reimbursement, is commercially available in the United States, and is recommended in international clinical guidelines. The tone is factual, focusing on transparency about executive shareholding and operational milestones.

What the data suggests

The CEO’s purchase of 500 ADS at an average price of $4.30 per ADS, split between $4.42 and $4.17 on two dates, demonstrates a modest increase in personal stake, now totaling 3,472,096 Ordinary Shares or 0.58% of the company. The aggregate purchase cost was $2,148. Each ADS represents 50 Ordinary Shares of £0.0025 each. The company’s kidneyintelX.dkd product has tested over 15,000 patients, is FDA-approved, and receives $950 per reportable result from Medicare. The product addresses a large market, with 15 million affected in the US and 8 million in the UK. The announcement provides no new financial performance data, revenue, or profitability figures, so the financial trajectory remains unclear. All disclosed figures are specific and verifiable, with no evidence of exaggeration or unsupported claims.

Analysis

The announcement is primarily a factual director dealing notice, disclosing the CEO's recent share purchases with full transaction details and resulting shareholding. The operational update on kidneyintelX.dkd is also factual, stating that the product has received FDA approval, Medicare reimbursement, is commercially available in the US, and is recommended in clinical guidelines. Over 15,000 patients have been tested, and the Medicare reimbursement rate is specified. Only one minor forward-looking statement is present, regarding ongoing deployment in physician group practices, but this is framed as an update on current activity rather than a speculative projection. There is no exaggerated or promotional language, and no claims of future financial performance or large-scale expansion without evidence. No large capital outlay or long-dated, uncertain returns are discussed. The tone is positive but proportionate to the facts disclosed.

Risk flags

• ●The CEO’s increased shareholding is a positive alignment signal but does not guarantee future company performance; insider purchases can reflect confidence but are not a substitute for operational or financial results.
• ●The announcement lacks any new financial performance data, such as revenue, cash flow, or profitability, making it difficult for investors to assess the company’s current financial health or growth trajectory.
• ●While kidneyintelX.dkd is FDA-approved and reimbursed by Medicare, the scale of commercial adoption and revenue generation is not quantified beyond the number of patients tested, leaving uncertainty about the pace and breadth of market penetration.

Bottom line

This is a routine director dealing notice: CEO James McCullough bought 500 ADS for $2,148, raising his stake to 0.58% of Renalytix’s issued share capital. The company provides clear detail on the transaction and reiterates the operational status of its kidneyintelX.dkd product, which is FDA-approved, Medicare-reimbursed at $950 per result, and has tested over 15,000 patients. No new financial results or revenue data are disclosed, so investors cannot assess recent business performance or growth. The CEO’s purchase signals personal confidence but does not substitute for broader financial or commercial evidence. The most actionable takeaway is the CEO’s modest increase in personal stake; further updates on revenue, adoption rates, or profitability would be needed for a more substantive investment view.

Announcement summary

(LSE:RENX) (OTCQB:RNLXY) Renalytix plc announced that on 11 September and 15 September 2026, James McCullough, Chief Executive Officer, purchased a total of 500 American Depositary Shares (ADS) at an average price of US$4.30 per ADS. Each ADS consists of 50 Ordinary Shares of £0.0025 each. Following these purchases, James McCullough holds an interest in 3,472,096 Ordinary Shares, representing 0.58% of the issued share capital of the Company, including shares held through The McCullough 2020 Irrevocable Trust. The purchases were made at prices of $4.42 per ADS for 250 ADS on 11 September and $4.17 per ADS for 250 ADS on 15 September, with an aggregated price of $2,148 for the 500 ADS. The financial instrument involved is American Depositary Shares (ADS), with identification code GB00BYWL4Y04. The transactions took place on the OTC New York market. Renalytix plc is a precision medicine diagnostics company focused on kidney disease, with its kidneyintelX.dkd product receiving FDA approval and Medicare reimbursement. KidneyintelX.dkd is now commercially available in the United States and is recommended in international chronic kidney disease clinical guidelines (KDIGO). Unrecognized and uncontrolled diabetic kidney disease affects approximately 15 million people in the United States and 8 million in the United Kingdom. Over 15,000 patients have been tested by kidneyintelX.dkd, generating substantial real-world performance data. Medicare reimbursement for kidneyintelX.dkd is established at $950 per reportable result. KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc., with Mount Sinai faculty and the Icahn School of Medicine at Mount Sinai holding equity in Renalytix.

Disagree with this article?